Impact of statin therapy on mortality and morbidity in patients with COVID-19

ABSTRACT

S40 Figure 1Mortality rates of high-, medium- and low-dose statin patient groups, converted to Atorvastatin equivalent2, and those not prescribed a statin. Medium-dose statin patients featured independent association with greater mortality rates (*p=0.039)[Figure omitted. See PDF]ConclusionWe highlight a cohort of patients who demonstrated greater mortality from COVID-19 when prescribed medium-dose statins, with an otherwise non-significant effect on mortality of statins of all doses when compared to non-statin patients. Medium-dose statin patients may be those at highest risk of cardiovascular sequelae of COVID-19 with multiple comorbidities, but unable to tolerate maximum doses. We advocate caution when prescribing statins with established COVID-19 therapies until specific groups are identified from prospective clinical trials that may benefit from their use.ReferencesZhang XJ, et al. Cell Metab 2020;32(2)176–187.e4. doi10.1016/j.cmet.2020.06.015Hu D, et al. Zhonghua Nei Ke Za Zhi 2015;54467–477